Idiopathic Parkinson's Disease Clinical Trial
Official title:
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
CERE-120 is an experimental drug that consists of an adeno-associated virus (AAV) that was
engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. Similar to
other growth factors (such as GDNF), neurturin is capable of restoring function and
protecting brain cells from further damage. The virus used in CERE-120 is not known to cause
disease in people.
CERE-120 is delivered directly to the brain cells most affected in Parkinson's disease - the
dopamine producing neurons. CERE-120 is injected during brain surgery. Once in place,
CERE-120 continuously produces neurturin.
During the first, open-label, part of the study (Phase 1), subjects with Parkinson's disease
received CERE-120 at one of two dose levels. In the second part of the study (Phase 2),
subjects were randomized 1:1 to receive CERE-120 or a "sham" surgery where no medication was
injected.
Participants in both phases of the study were followed for up to five years after surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03665493 -
Dopamine Effect on Inhibitory Control
|
N/A | |
| Completed |
NCT02227355 -
Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease
|
N/A | |
| Completed |
NCT01026428 -
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
|
Phase 1/Phase 2 | |
| Completed |
NCT00664157 -
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus
|
N/A | |
| Completed |
NCT04524143 -
The Acute Effect of Cervical Mobilization in Parkinson's Disease
|
N/A | |
| Completed |
NCT05107531 -
Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
|
||
| Completed |
NCT04524182 -
The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease
|
N/A | |
| Completed |
NCT01968031 -
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
|
Phase 3 | |
| Completed |
NCT01970813 -
Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease
|
N/A | |
| Completed |
NCT01221948 -
Vercise Implantable Stimulator for Treating Parkinson's Disease
|
Phase 2 | |
| Terminated |
NCT01028586 -
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
|
Phase 3 | |
| Completed |
NCT00239564 -
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02240030 -
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
|
Phase 3 | |
| Completed |
NCT00605683 -
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
|
Phase 3 | |
| Completed |
NCT00400634 -
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
| Completed |
NCT02565628 -
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT01617135 -
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
|
Phase 2 | |
| Completed |
NCT01606670 -
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
|
||
| Terminated |
NCT00261781 -
Walking Capacity in Parkinson's Disease (PD-Walk)
|
N/A |